ArticleInfluenza and other respiratory viruses2023
Inpatient burden of respiratory syncytial virus in children ≤2 years of age in Germany: A retrospective analysis of nationwide hospitalization data, 2019-2022.
Article in Influenza and other respiratory viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- Prevalence of common respiratory viruses of infants with respiratory tract infections in European countries in the past decade: a systematic review and meta-analysis comparing between the pre-COVID-19, pandemic, and post-COVID-19 periods.European journal of pediatrics · 2026Pooled it
- Characteristics of influenza, SARS-CoV-2, and RSV surveillance systems that utilise ICD-coded data: a systematic review.Journal of global health · 2025Pooled it
- Burden of respiratory syncytial virus (RSV) infection in Germany: a systematic review.BMC infectious diseases · 2024Pooled it
- Clinical and Economic Inpatient Burden of Influenza and Influenza-Like Illness in Germany 2019-2025: Analysis of Nationwide Hospital Data.Infectious diseases and therapy · 2026Article
- Health Care Resource Utilization and Associated Costs Across Proteinuria and Declining Kidney Function in Patients With IgA Nephropathy: A Retrospective Study in Three European Countries.Kidney medicine · 2026Article
- Real-world impact of nirsevimab on RSV hospitalizations in children under 2 years of age: retrospective monocentric study in a large German tertiary pedatric center.Molecular and cellular pediatrics · 2026Article
- Epidemiology of respiratory syncytial virus in a German hospital before, during and after the COVID-19 pandemic - a real world monocentric analysis over ten years.Frontiers in pediatrics · 2026Article
- Observational
- [RSV versus SARS-CoV-2 in children : Comparison of hospitalised cases].Wiener medizinische Wochenschrift (1946) · 2025Article
- RSV Monitoring in Germany: A Critical Overview of Available Surveillance Systems.Journal of clinical medicine · 2025Review
- Dynamics of RSV hospitalization rates in ≤ 2-year-old children between 2020-2023 in Europe.European journal of pediatrics · 2025Article
- Kinetic Patterns of Antibiotic Consumption in German Acute Care Hospitals from 2017 to 2023.Antibiotics (Basel, Switzerland) · 2025Article
- Article
- Article
- Effectiveness and efficiency of immunisation strategies to prevent RSV among infants and older adults in Germany: a modelling study.BMC medicine · 2024Article
- Article
- COVID-19, Influenza, and RSV in Children and Adults: A Clinical Comparative Study of 12,000 Cases.Journal of clinical medicine · 2024Article
- Retrospective Analysis of RSV Infection in Pediatric Patients: Epidemiology, Comorbidities, Treatment, and Costs in Dubai (2014-2023).Journal of health economics and outcomes research · 2024Article
- Inpatient burden of respiratory syncytial virus in children ≤2 years of age in Germany: A retrospective analysis of nationwide hospitalization data, 2019-2022.Influenza and other respiratory viruses · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundRespiratory syncytial virus (RSV) causes respiratory tract disease in seasonal waves, primarily in infants and young children. This study aims to quantify the number of RSV-related hospitalizations in children ≤2 years of age and to determine corresponding resource use and costs in Germany.
methodsWe retrospectively analyzed population-wide hospital data from the Institute for the Hospital Remuneration System (InEK) from 2019 to 2022. RSV cases were identified using the RSV-specific 10th revision of the International Classification of Diseases (ICD-10) codes J12.1, J20.5, and J21.0. The RSV-associated proportion of all hospitalizations caused by severe acute respiratory infections (SARIs), clinical manifestations, length of stay (LOS), intensive care unit (ICU) admissions, ventilation rates, and hospitalization costs were retrieved.
resultsWe identified 98,220 hospitalizations (26,052, 15,407, 31,362, and 25,399 in 2019, 2020, 2021, and 2022, respectively) with a principal RSV diagnosis in children aged ≤2 years in Germany. The majority of RSV hospitalizations (73,178) occurred in infants (<1 year), with annual incidence rates ranging from 14.9 to 28.6 per 1000 population. Fifty-eight percent of all SARI hospitalizations in this age group were attributable to RSV. In children aged ≤2 years, mean LOS was 4.5 days, 6.1% of cases were admitted to ICU, and 5.3% of cases were ventilated. Mean hospitalization costs per case ranged from €3001 to €3961 over the study period.
conclusionsRSV causes substantial disease burden and is a leading cause of SARI-related hospital admissions of children ≤2 years of age in Germany. Our results confirm the need to explore and evaluate strategies to prevent RSV in infants and young children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.